Tamoxifen exerts anti-peritoneal fibrosis effects by inhibiting H19-activated VEGFA transcription

Tamoxifen exerts anti-peritoneal fibrosis effects by inhibiting H19-activated VEGFA transcription

Abstract Background Peritoneal dialysis (PD) remains limited due to dialysis failure caused by peritoneal fibrosis. Tamoxifen (TAM), an inhibitor of estrogen receptor 1 (ESR1), has been reported to treat fibrosis, but the underlying mechanism remains unknown. In this study, we sought to explore whet...

Full description

Bibliographic Details
Main Authors: Tingting Zhao, Zhengyu Sun, Xueli Lai, Hongtao Lu, Lulu Liu, Shuangxi Li, Ji-hang Yuan, Zhiyong Guo
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Journal of Translational Medicine
Subjects:
Peritoneal fibrosis
Tamoxifen
Estrogen receptor 1
Long non-coding RNA H19
Vascular endothelial growth factor A
Online Access:https://doi.org/10.1186/s12967-023-04470-3

Internet

https://doi.org/10.1186/s12967-023-04470-3

Similar Items